The reduction from above 5% to 4.8% is minor and typical for a passive index manager rebalancing. Monitor for any further filings that would indicate a continued reduction trend, but this filing alone does not signal a change in investment thesis.
BCRX drugs
BCRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $7.53entry
- T+1 · 6d ago +1.59%α +0.27% · $7.65
- T+4 · todayOpen
- T+5 · in 3h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
State Street Corporation filed a Schedule 13G disclosing a passive 4.8% stake in BioCryst Pharmaceuticals as of September 30, 2026, down from a prior 5%+ position. The filing confirms continued institutional ownership but a slight reduction in holdings, with no activist intent indicated.
Key Financial Metrics
Key Facts
- State Street Corporation filed a Schedule 13G on November 10, 2026, reporting beneficial ownership of 12,294,412 shares of BioCryst common stock as of September 30, 2026.
- The stake represents 4.8% of shares outstanding, down from a prior 5%+ position (previous 13G filings in August and May 2026).
- The filing certifies passive intent under Rule 13d-1(b), with no purpose of changing or influencing control.
- State Street is a major index fund manager; this is a routine portfolio adjustment.
- BioCryst reported strong Q3 2026 results on November 4, 2026: total revenue $180.3M (+13% YoY), GAAP net income $37.9M, and raised full-year guidance.
Financial Impact
State Street reduced its stake from above 5% to 4.8%, representing a decrease of approximately 601,450 shares (based on prior filing data). At a ~$2.0B market cap, the stake value is approximately $96M.
Risk Factors
- State Street's reduction below 5% removes the requirement for future 13G filings, reducing transparency on their position.
- The filing date (November 10) is after BioCryst's strong Q3 earnings (November 4), so the reduction may have occurred before the earnings release.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000093751-26-000622 |
| Document: 0000093751-26-000622-index.html | 0000093751-26-000622 |
| Document: 0000093751-26-000622.txt | 0000093751-26-000622 |
Track record
20 reports on BCRX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.01% at T+20 after the Feb 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $7.61 Now $7.45 −2.10% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $7.53 Now $7.45 −1.06% settles Feb 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
- Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers